Keyphrases
Ex Vivo Model
100%
Leishmania (Viannia) Panamensis
100%
Miltefosine
100%
Azole Drugs
100%
Posaconazole
100%
Oral Azoles
100%
L. Panamensis
83%
Treatment Efficacy
50%
High Potency
33%
Voriconazole
33%
Itraconazole
33%
Fluconazole
33%
Clinical Strains
33%
Index-based
33%
Antimony
33%
Fractional Inhibitory Concentration Index
33%
Sensitive Lines
33%
Leishmania
16%
Cutaneous Leishmaniasis
16%
Antileishmanial
16%
Novel Therapeutics
16%
Quantitative PCR
16%
Reverse Transcription
16%
Drug Combination
16%
Combination Therapy
16%
Peripheral Blood Mononuclear Cells
16%
Drug Resistance
16%
Treatment Failure
16%
Drug Concentration
16%
Luciferase
16%
Synergistic Activity
16%
Antimonial Drugs
16%
Low Potencies
16%
Resistant Lines
16%
Oral Combination
16%
Free Drug Concentration
16%
Antileishmanial Effects
16%
Isobologram
16%
Parasite Quantification
16%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Leishmania braziliensis
100%
Miltefosine
100%
Posaconazole
100%
Pyrrole
100%
Drug Concentration
33%
Fluconazole
33%
Itraconazole
33%
Voriconazole
33%
Skin Leishmaniasis
16%
Leishmania
16%
Combination Therapy
16%
Luciferase
16%
Drug Resistance
16%
Antimonial
16%
Combination Drug
16%
Immunology and Microbiology
Leishmania braziliensis
100%
Infection
100%
Fractional Inhibitory Concentration Index
50%
Blood Plasma
25%
Leishmania
25%
Cutaneous Leishmaniasis
25%
Quantitative Reverse Transcription Polymerase Chain Reaction
25%
Reverse Transcription
25%
Drug Concentration
25%
Drug Resistance
25%
Peripheral Blood Mononuclear Cell
25%